The Policy Cycle

In this episode of Bench to Boardroom, we explore why the most successful life sciences leaders view health policy, regulation, and macroeconomic forces not as isolated disruptions, but as recurring cycles that shape strategic decision-making. From U.S. tariffs, the Inflation Reduction Act (IRA), and Most Favored Nation (MFN) pricing proposals to evolving EU pharmaceutical legislation, orphan drug incentives, and supply security initiatives, the discussion examines how these developments are influencing portfolio strategy, launch sequencing, manufacturing investment, and global commercialization. Through historical perspective and recent examples, the episode argues that enduring value is created by organizations that build resilient portfolios, diversify capabilities, embrace true innovation, and anticipate policy cycles rather than simply reacting to them. Ultimately, the leaders who succeed are those who learn from history, think holistically, and transform uncertainty into strategic advantage.